Harbin Pharmaceutical Group (SHSE:600664) Strong Profits May Be Masking Some Underlying Issues
Harbin Pharmaceutical Group (SHSE:600664) Strong Profits May Be Masking Some Underlying Issues
Harbin Pharmaceutical Group Co., Ltd. (SHSE:600664) just released a solid earnings report, and the stock displayed some strength. However, we think that shareholders should be cautious as we found some worrying factors underlying the profit.
哈藥股份剛剛發佈了一份穩健的收益報告,股票表現出一些實力。然而,我們認爲股東們應該謹慎,因爲我們發現了一些令人擔憂的利潤潛在因素。
The Impact Of Unusual Items On Profit
除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。
Importantly, our data indicates that Harbin Pharmaceutical Group's profit received a boost of CN¥100m in unusual items, over the last year. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).
重要的是,我們的數據顯示,哈藥股份的利潤在過去一年中因飛凡項目而獲得了10000萬元人民幣的增長。我們不能否認,更高的利潤通常讓我們感到樂觀,但我們更希望利潤能夠持續。我們研究過全球大多數上市公司的數據,非常普遍的是飛凡項目通常是一次性的。而這正是你所期望的,鑑於這些提振被描述爲「飛凡」。假設這些飛凡項目今年不再出現,那麼我們希望利潤在明年會較弱(如果沒有業務增長的話)。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Harbin Pharmaceutical Group.
注意:我們始終建議投資者檢查資產負債表的實力。點擊這裏查看我們對哈藥股份資產負債表分析。
Our Take On Harbin Pharmaceutical Group's Profit Performance
我們對哈藥股份的利潤表現看法
Arguably, Harbin Pharmaceutical Group's statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Harbin Pharmaceutical Group's true underlying earnings power is actually less than its statutory profit. In further bad news, its earnings per share decreased in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. You can see our latest analysis on Harbin Pharmaceutical Group's balance sheet health here.
可以說,哈藥股份的法定收益受到飛凡項目利潤的扭曲。因此,我們認爲哈藥股份真正的基本盈利能力實際上低於其法定利潤。更糟糕的是,過去一年,其每股收益有所下降。最終,如果您想正確了解公司,除了上述因素之外,還需要考慮更多。雖然重要的是考慮損益表,您還可以通過查看資產負債表了解很多關於一家公司的信息。您可以在這裏查看我們對哈藥股份資產負債表健康狀況的最新分析。
Today we've zoomed in on a single data point to better understand the nature of Harbin Pharmaceutical Group's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
今天我們聚焦於單一數據點,以更好地了解哈藥股份利潤的本質。但還有許多其他方式可以幫助您了解一家公司。例如,許多人認爲高股本回報率是有利的業務經濟狀況的指標,而其他人則喜歡『跟着錢走』,尋找內部人員正在買入的股票。雖然這可能需要您做些研究,您可能會發現這裏列出的擁有高股本回報率的公司集合,或者這份擁有重要內部持股的股票清單對您有所幫助。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。